Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06062602 · ClinicalTrials.gov registry record · Early Phase 1

PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC

A Early Phase 1 study of Head and Neck Squamous Cell Carcinoma, sponsored by Presage Biosciences.

Completed
Registry status
Early Phase 1
Development phase
15
Enrollment target
4
Study locations

NCT06062602 is a Early Phase 1 study of Head and Neck Squamous Cell Carcinoma that has completed, run by Presage Biosciences. The registered enrollment target is 15 participants, below the 117-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (87% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06062602, a Early Phase 1 study of Head and Neck Squamous Cell Carcinoma, has completed, sponsored by Presage Biosciences.

COMPLETED
Registry status
Early Phase 1
Development phase
15 participants
Enrollment target
4
Study locations

Study Summary

This is a multi-center, open-label Phase 0 substudy designed to study the localized pharmacodynamics (PD) of TAK-676 alone or in combination with Carboplatin, 5-FU, or Paclitaxel within the tumor microenvironment (TME) when administered intratumorally in microdose quantities via the CIVO device in patients diagnosed with Head and Neck Squamous Cell Carcinoma presenting with a surface accessible solid tumor for which there is a scheduled surgical intervention. This substudy is a cohort of the PBI-MST-01 Master Protocol.

Conditions Studied

Head and Neck Squamous Cell Carcinoma

Interventions

  • DRUG Carboplatin
  • DRUG Paclitaxel
  • DRUG 5-FU
  • DRUG TAK-676
  • COMBINATION_PRODUCT TAK-676 + Carboplatin

Study Locations (4)

Louisiana

  • LSU Health Sciences Center - Shreveport - Shreveport

New York

  • Montefiore Medical Center - The Bronx

Ohio

  • University of Cincinnati Health - Cincinnati

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2021-07-26
Est. Completion 2022-11-15
Phase Early Phase 1

Sponsor

Presage Biosciences

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06062602

The ClinicalTrials.gov registry entry for NCT06062602 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 117-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (87% lower). The listed sponsor is Presage Biosciences, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Head and Neck Squamous Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT06062602 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Louisiana, New York, Ohio.

Frequently Asked Questions

What is clinical trial NCT06062602 about?

NCT06062602 is a clinical study titled "PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC". This is a multi-center, open-label Phase 0 substudy designed to study the localized pharmacodynamics (PD) of TAK-676 alone or in combination with Carboplatin, 5-FU, or Paclitaxel within the tumor microenvironment (TME) when administered intratumorally in microdose quantities via the CIVO device in p...

What is the current status of trial NCT06062602?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2021-07-26. Estimated completion is 2022-11-15.

What conditions does trial NCT06062602 study?

This clinical trial studies the following conditions: Head and Neck Squamous Cell Carcinoma.

What interventions are being tested in trial NCT06062602?

The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), 5-FU (DRUG), TAK-676 (DRUG), TAK-676 + Carboplatin (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT06062602?

This trial is sponsored by Presage Biosciences, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06062602 being conducted?

This trial has 4 study locations across Louisiana, New York, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Squamous Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Head and Neck Squamous Cell Carcinoma

All registered trials for this condition

Louisiana

All trials with a study site in Louisiana

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.